Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$950.87

12.27 (1.31%)

, FIT

Fitbit

$6.98

0.41 (6.24%)

07:56
09/28/17
09/28
07:56
09/28/17
07:56

Amazon has 5,000 employees developing Echo, Alexa, CNBC reports

Amazon (AMZN) currently has 5,000 employees developing its Echo and Alexa products which is more workers than Fitbit (FIT) and GoPro (GPRO) have combined, CNBC reports, citing comments made by Amazon hardware chief Dave Limp. Amazon, which said there were roughly 1,000 employees working on the platforms in May 2016, has also listed about 1,500 job openings for positions related to Alexa and Echo. Reference Link

AMZN

Amazon.com

$950.87

12.27 (1.31%)

FIT

Fitbit

$6.98

0.41 (6.24%)

GPRO

GoPro

$11.69

0.18 (1.56%)

  • 03

    Oct

  • 04

    Oct

  • 08

    Oct

  • 22

    Oct

  • 07

    Dec

  • 11

    Dec

AMZN Amazon.com
$950.87

12.27 (1.31%)

09/27/17
NEED
09/27/17
NO CHANGE
NEED
Amazon.com product doesn't compete with Vonage, says Needham
Needham analyst Richard Valera says that Vonage's (VG) shares fell 2% yesterday due to a blog which reported that Amazon (AMZN) "added a two-way SMS capability to its Pinpoint product." However, the analyst says that Pinpoint is "narrowly focused on enabling user engagement campaigns for app developers and not a general purpose SMS/voice API, such as offered by" Vonage. The analyst adds that Vonage may be "providing the back-end" of Pinpoint. He thinks that Vonage's UCaaS and CPaaS businesses.have "good momentum," and he keeps a $9.50 price target and a Buy rating on the shares.
09/27/17
WBLR
09/27/17
NO CHANGE
WBLR
Outperform
Kornit Digital long-term opportunity remains unchanged, says William Blair
William Blair analyst Brian Drab believes Kornit Digital's (KRNT) shortfall in Q3 is a function of timing and that the company's fundamental long-term opportunity remains unchanged. The valuation multiple in the near term, however, will be "tempered given volatility associated with customer concentration," Drab tells investors in a research note. The analyst thinks Amazon (AMZN) is the customer experiencing the permitting issue, which he notes management expects to be resolved in the next few months. He keeps an Outperform rating on the shares.
09/28/17
BERN
09/28/17
NO CHANGE
BERN
Amazon will enter retail pharmacy industry, says Bernstein
Bernstein analyst Lance Wilkes thinks Amazon will enter the retail pharmacy industry, especially because it is a large and disruptable market. The analyst believes Amazon is well positioned to address/impact the major customer issues in this market, and expects it will need to partner with or acquire a PBM to drive volume growth. Wilkes is also increasingly concerned that Amazon's entry will negatively impact PBM earnings levers.
09/28/17
MSCO
09/28/17
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says Perrigo opportunity at Amazon 'more hype' than sales driver
Morgan Stanley analyst David Risinger believes online sales are unlikely to drive higher net revenue for Perrigo (PRGO) in the U.S. because such purchases will likely cannibalize existing sales via traditional brick and mortar retailers. Amazon (AMZN) currently sells Perrigo's GoodSense low-cost brand and Risinger sees it as possible that Amazon eventually develops its own brand and sources private label products from Perrigo and others, but this would also likely cannibalize GoodSense, he tells investors. The analyst, who noted "this is not a negative stock call," keeps an Equal Weight rating on Perrigo.
FIT Fitbit
$6.98

0.41 (6.24%)

08/29/17
DBAB
08/29/17
NO CHANGE
Target $5.5
DBAB
Hold
Fitbit may take share in smartwatch category, says Deutsche Bank
Deutsche Bank analyst Sherri Scribner likes that Fitbit's (FIT) first smartwatch, Ionic, is focused on the health and wellness category, where share notes the company has made a name for itself. The watch is platform agnostic, which provides a "compelling" offering for non-Apple (AAPL) users, and has a 4-plus day battery life, all at a lower price point than Apple Watch, Scribner tells investors in a research note. She believes that while Fitbit is late to the smartwatch category, the company may be able to capture share. The analyst keeps a Hold rating on the stock with a $5.50 price target.
08/29/17
OPCO
08/29/17
NO CHANGE
Target $8
OPCO
Outperform
Oppenheimer applauds Fitbit new products announcement
Oppenheimer analyst Andrew Uerkwitz says that with Fitbit's announcement of a smart watch, headphones, gen2 scale, and a guidance/coaching app, he sees the company doubling down on fitness and moving well beyond basic activity trackers. The analyst applauds these moves and sees them as something that is probably a year or two late. If these launches are successful, Uerkwitz believes the shares could re-rate much higher-not only on a sign of better execution, but as a connected health company being more valuable than a fitness tracker hardware company. He reiterates an Outperform rating and $8 price target on the shares.
09/07/17
PIPR
09/07/17
NO CHANGE
PIPR
Overweight
Dexcom partnership with Fitbit has 'deeper potential,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien noted that Fitbit (FIT) and Dexcom (DXCM) have announced a collaboration that will initially allow Fitbit Iconic users to see their CGM data on their wrists, but he believes there is a "deeper potential" for the two to work together and potentially add a heart rate monitor to a future closed loop system. However, he notes he has not confirmed with either company that any such plans are in the works. O'Brien remains positive on Dexcom shares and keeps an Overweight rating on the name.
09/13/17
STFL
09/13/17
NO CHANGE
Target $6
STFL
Hold
New Apple Watch will be 'stiff competition' for Fitbit Ionic, says Stifel
Stifel analyst Jim Duffy pointed to some advantages favoring Fitbit's (FIT) Ionic over Apple's (AAPL) Watch Series 3 - such as compatibility with non-iOS devices, longer battery life and a narrow price advantage - but he also thinks the Series 3 will present "stiff competition for consumer attention" during the Holidays. He keeps a Hold rating and $6 price target on Fitbit on the heels of Apple's launch event yesterday.
GPRO GoPro
$11.69

0.18 (1.56%)

09/01/17
MSCO
09/01/17
NO CHANGE
Target $60
MSCO
Overweight
Morgan Stanley still convinced computer vision will be major cycle for Ambarella
Morgan Stanley analyst Joseph Moore said he'd foreseen the possibility for some near-term challenges for Ambarella's (AMBA) business outside of GoPro (GPRO), but the shortfall and near-term guidance miss was bigger than he expected due to several issues, particularly drones. However, he said the company's additional color on its upcoming computer vision portfolio was encouraging and he remains convinced computer vision will be a "major product cycle that matters." Moore cut his Ambarella estimates for next year "materially" and lowered his price target on the stock to $60 from $65, though he maintains his Overweight rating on the shares.
09/07/17
JPMS
09/07/17
NO CHANGE
Target $15
JPMS
Overweight
GoPro price target raised to $15 from $13 at JPMorgan
JPMorgan analyst Paul Coster adjusted his Q3 estimates for GoPro after the company reported that it now expects revenues and margins to come in at the high end of its previous guidance and he is also raising his multiple on the stock to account for its solid execution ahead of the launch of the Hero 6 camera. Given the raised multiple, Coster increased his price target on the stock to $15 from $13 and keeps an Overweight rating on GoPro shares.
09/08/17
SBSH
09/08/17
NO CHANGE
Target $10.5
SBSH
Neutral
GoPro price target raised to $10.50 from $9.50 at Citi
Citi analyst Stanley Kovler raised his price target for GoPro shares to $10.50 following the company's positive preannouncement. Sell-through in July was strong and good sales were experienced in August as well across all regions, Kovler tells investors in a research note. He maintains a Neutral rating on GoPro.
09/21/17
CLVD
09/21/17
NO CHANGE
CLVD
GoPro unit and earnings estimates raised through 2018 at Cleveland Research
Cleveland Research analyst Ben Bollin raised GoPro's unit and earnings assumptions through 2018. The analyst said feedback indicates 2017 units are trending to 4.7-4.8M units, versus 4.6-4.7M prior, and 2018 expectations suggest flat year-over-year performance, versus a low $4M range prior. The analyst adds Karma sales appear better on improved availability and the Wynit bankruptcy is not expected to be a significant headwind. Bollin rates GoPro shares a Neutral.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.